Bailard’s Terns Pharmaceuticals TERN Stock Holding History

Bailard’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,300	Closed	-$50K	–	757
2022 Q2	$50K	Buy	+20,300	New	+$40.5K	﹤0.01%	672

Other funds holding TERN

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bailard's TERN Position: Q3 2022 in Review

Bailard sold out of Terns Pharmaceuticals (TERN) in Q3 2022, closing a stake of 20,300 shares — an estimated $50K sold.

Bailard first reported a position in TERN in Q2 2022 and held it in 1 quarter. The position peaked at $50K in Q2 2022. 45 funds tracked by Wall St. Rank hold TERN as of Q3 2022.

Bailard reported no remaining Terns Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Bailard sold 20,300 Terns Pharmaceuticals shares in Q3 2022, an estimated $50K.
Bailard first reported a position in Terns Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Bailard's Terns Pharmaceuticals position peaked at $50K in Q2 2022.
45 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.